1. Challenges and opportunities in New Zealand’s pharmaceutical scene Kevin Sheehy – Chief Executive, Medicines New Zealand Dalton Kelly – Chief Executive, New Zealand Cancer Society Assoc. Prof. Ken Whyte – University of Auckland Medical School

2. Medicines Access: Looking ahead Kevin Sheehy General Manager Medicines New Zealand Opportunities for better health of patients are a challenge for funders

3. Understanding people’s needs Researc h and clinical trials Living longer with better quality Clinical Research It’s about improving healthcare How do we sustain this improvement in healthcare?

4. Opportunities Personalised medicine Integrated decision making a complex problem Medicine pipeline developments Challenging demographics Ageing population – degenerative illness Later retirement Funding challenges Medicines Access: Looking ahead

5. “Genetics plays an important role in most diseases: cancer, obesity, diabetes, cardiovascular, neurologic and psychiatric diseases. All of medicine.” - Professor of Genetics at Harvard Medical School and first Scientific Director of the Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Dr. Raju Kucherlapati Throat swabs or genetic tests  Each have the ability to better target treatment  Require integrated decision making (discussion between the budget silos) Many new treatments are expensive to develop but can improve cost effectiveness by treating those who respond best Personalised medicine

6. Contributing to New Zealand’s economic prosperity Savings vs improved health Include costs not currently considered Back to work Cost of disease to society Compare to other health interventions Ministry work commencing Better understand value proposition Integrated decision making

7. Over 20 new medicines per year registered by FDA  Cancer  Immunology  Virology  Metabolic diseases  Neurology Biologics Increasing development complexity and costs New indications Medicine pipeline developments

8. Old Model One chemist One week One molecule New Model One chemist One computer One robot One week 10,000 Molecules Medicine pipeline developments cont

9. Age related illness  Non Communicable Diseases  Heart, brain, metabolic, cancer Ageing effect dominant reason for increasing cancer Over 65s increasing by 4000 people per month Retiring later? R&D improving treatments e.g. Biologicals for rheumatoid arthritis Challenging demographics

10. Medicine = medical device = Surgery ? But they are all fruit! Healthcare investments can and should be compared Funding challenges

11.  Making Named Patient Pharmaceutical Assessment (NPPA) work  Hospital medicines  Greater transparency/engagement and responsiveness  Measuring performance  Understanding unmet needs Current funding system challenges

12. Questions?